Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Outstanding and Exercisable

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended MARCH 31, 2023

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 000-54617

(Exact name of registrant as specified in its charter)

Delaware		45-4535739
State or other jurisdiction of		(I.R.S. Employer
Incorporation or organization		Identification No.)

7051 Eton Avenue

Canoga Park, CA 91303

(Address of principal executive offices)

(818) 883-7043

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging Growth Company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered

The number of shares of the Registrant’s common stock outstanding as of June 27, 2023, was 36,390,478.

TABLE OF CONTENTS

PART I
Item 1.	Financial Statements (Unaudited)	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21
Item 4.	Controls and Procedures	21

PART II
Item 1.	Legal Proceedings	22
Item 1A.	Risk Factors	22
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3.	Defaults Upon Senior Securities	22
Item 4.	Mine Safety Disclosures	22
Item 5.	Other Information	22
Item 6.	Exhibits	23
	Signatures	24

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

US NUCLEAR CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31,			December 31,
	2023			2022
	(unaudited)			(audited)
ASSETS
CURRENT ASSETS
Cash	$	214,236		$	126,109
Accounts receivable, net		184,378			329,858
Note receivable		14,000			-
Inventories		2,156,422			2,024,664
Prepaid expenses and other current assets		-			26,370
TOTAL CURRENT ASSETS		2,569,036			2,507,001

Property and equipment, net		5,214			6,501
Investments		4,539			10,059
Acquisition deposit		15,000			15,000
Goodwill		570,176			570,176
TOTAL ASSETS	$	3,163,965		$	3,108,737

LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES
Accounts payable	$	61,313		$	100,398
Accounts payable - related party		322,000			280,000
Accrued liabilities		750,053			688,422
Accrued compensation - officers		740,000			695,000
Customer deposit		93,694			88,694
Notes payable		5,272			9,574
Convertible debt, net of debt discount		510,135			412,953
Note payable to shareholder		916,979			874,679
Line of credit		307,937			307,321
TOTAL CURRENT LIABILITIES		3,707,383			3,457,041

TOTAL LIABILITIES		3,707,383			3,457,041

SHAREHOLDERS’ EQUITY:
Common stock, $0.0001 par value; 100,000,000 shares authorized, 34,556,242 and 31,621,242 shares issued and outstanding		3,456			3,162
Common shares to be issued		-			39,000
Additional paid in capital		15,250,540			14,740,401
Accumulated deficit		(15,797,414	)		(15,130,867	)
TOTAL SHAREHOLDERS’ EQUITY		(543,418	)		(348,304	)
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	3,163,965		$	3,108,737

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

US NUCLEAR CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

	Three Months Ended
	March 31,
	2023			2022

Sales	$	647,706		$	339,515
Cost of sales		212,117			112,238
Gross profit		435,589			227,277

Operating expenses
Selling, general and administrative expenses		735,825			873,503
Total operating expenses		735,825			873,503

Loss from operations		(300,236	)		(646,226	)

Other income (expense)
Interest expense		(22,140	)		(3,417	)
Equity loss in investment		(8,059	)		-
Loss on deconsolidation		(2,539	)		-
Amortization of debt discount		(331,559	)		-
Total other income (expense)		(364,298	)		(3,417	)

Loss before provision for income taxes		(664,534	)		(649,643	)

Provision for income taxes		-			-

Net loss	$	(664,534	)	$	(649,643	)

Deemed dividend for down-round provision in warrants		(2,013	)		-

Net loss attributed to common stockholders	$	(666,547	)	$	(649,643	)

Weighted average shares outstanding - basic and diluted		32,634,839			28,428,215

Loss per shares - basic and diluted	$	(0.02	)	$	(0.02	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

US NUCLEAR CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY

(unaudited)

								Additional					Total
	Common Stock				Common Stock			Paid-in		Accumulated			Shareholders’
	Shares		Amount		Payable			Capital		Deficit			Equity
Balance, December 31, 2022		31,621,242	$	3,162	$	39,000		$	14,740,401	$	(15,130,867	)	$	(348,304	)

Issuance of common stock for services		1,875,000		188					224,163		-			224,350
Issuance of common stock for debt and interest		800,000		80					119,920					120,000
Deemed dividend for down-round provision in warrants									2,013		(2,013	)
Common shares to be issued for services		260,000		26		(39,000	)		38,974					-
Additional BCF discount for down-round provision on notes									122,531					122,531
Investment in Averox									2,539					2,539
Net loss											(664,534	)		(664,534	)

Balance, March 31, 2023		34,556,242	$	3,456	$	-		$	15,250,540	$	(15,797,414	)	$	(543,418	)

							Additional					Total
	Common Stock				Common Stock		Paid-in		Accumulated			Shareholders’
	Shares		Amount		Payable		Capital		Deficit			Equity
Balance, December 31, 2021		28,353,215	$	2,835	$	-	$	13,508,582	$	(13,070,148	)	$	441,269

Issuance of common stock for services		75,000		8		-		22,492		-			22,500
Net loss		-		-		-		-		(649,643	)		(649,643	)

Balance, March 31, 2022		28,428,215	$	2,843	$	-	$	13,531,074	$	(13,719,791	)	$	(185,874	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

US NUCLEAR CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

	Three Months Ended
	March
	2023			2022

OPERATING ACTIVITIES
Net loss	$	(664,534	)	$	(649,643	)
Adjustment to reconcile net loss to net cash used in operating activities:

Depreciation and amortization		1,287			13,659
Issuance of common stock for services		234,100			62,526
Debt discount amortization		331,559			-
Financing costs		3,500			-
Loss on deconsolidation		2,539			-
Loss on equity investment		8,059			-

Changes in operating assets and liabilities:
Accounts receivable		145,480			82,541
Inventories		(131,758	)		58,971
Prepaid		16,620			(713	)
Accounts payable		(39,085	)		(29,224	)
Accounts payable - related parties		42,000			42,000
Accrued liabilities		66,285			51,610
Accrued compensation - officers		45,000			45,000
Customer deposits		5,000			(15,591	)
Net cash used in operating activities		66,052			(338,864	)

INVESTING ACTIVITIES
Purchase of property and equipment		-			(12,629	)
Cash paid upon deconsolidation		(2,539	)		-
Note receivable		(14,000	)		-
Net cash used in investing activities		(16,539	)		(12,629	)

FINANCING ACTIVITIES
Net borrowings (repayments) under lines of credit		616			(2,662	)
Proceeds from issuance of note payable shareholder		42,300			179,000
Repayments of notes payable		(4,302	)		(5,307	)
Stock issued for debt issuance		-			-
Net cash provided by financing activities		38,614			171,031

NET INCREASE (DECREASE) IN CASH		88,127			(180,462	)

CASH
Beginning of period	$	126,109		$	246,317
End of period	$	214,236		$	65,855

Supplemental disclosures of cash flow information
Taxes paid	$	-		$	-
Interest paid	$	27		$	3,417

Non-cash disclosures:
Common stock issued for conversion of debt and interest	$	116,500		$	-
Deemed dividend on down-round provision on warrants	$	2,013		$	-
Additional BCF on down-round provision on convertible notes payable	$	122,531		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

US NUCLEAR CORP. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE QUARTER ENDED MARCH 31, 2023

Note 1 – Organization

Organization and Line of Business

US Nuclear Corp., formerly known as APEX 3, Inc., (the “Company” or “US Nuclear”) was incorporated under the laws of the State of Delaware on February 14, 2012.

On May 31, 2016, the Company entered into an Asset Purchase Agreement with Electronic Control Concepts (“ECC”) whereby the Company purchased certain tangible and intangible assets of ECC.

The Company is engaged in developing, manufacturing and selling radiation detection and measuring equipment. The Company markets and sells its products to consumers throughout the world.

Note 2 – Basis Presentation

Interim financial statements

The unaudited interim financial statements included herein, presented in accordance with United States generally accepted accounting principles and stated in US dollars, have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosure normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosure is adequate to make the information presented not misleading.

These statements reflect all adjustment, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for fair presentation of the information contained therein. It is suggested that these interim financial statements be read in conjunction with the financial statements of the Company for the year ended December 31, 2022 and notes thereto included in the Company’s annual report on Form 10-K filed on May 12, 2023. The Company follows the same accounting policies in the preparation of interim report. Results of operations for the interim period are not indicative of annual results.

Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company recorded a net loss of $664,534 for the three months ended March 31, 2023 and had an accumulated deficit of $15,797,414 as of March 31, 2023, which raises substantial doubt about its ability to continue as a going concern.

The Company’s ability to continue as a going concern is dependent upon its ability to generate profitable operations in the future and/or obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management has plans to seek additional capital through some private placement offerings of debt and equity securities. These plans, if successful, will mitigate the factors which raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries which include Optron, Overhoff Technology Corporation (“Overhoff”), and its wholly-owned subsidiary, Electronic Control Concepts (“ECC”), have been prepared in conformity with accounting principles generally accepted in the United States of America. All significant intercompany transactions and balances have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. It is possible that accounting estimates and assumptions may be material to the Company due to the levels of subjectivity and judgment involved.

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. There were no cash equivalents as of March 31, 2023 and December 31, 2022.

Concentration of credit risk

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company places its cash with high quality financial institutions and at times may exceed the FDIC insurance limit. The Company has not and does not anticipate incurring any losses related to this credit risk.

Accounts Receivable

The Company maintains reserves for potential credit losses for accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. Reserves are recorded based on the Company’s historical collection history. Allowance for doubtful accounts as of March 31, 2023 and December 31, 2022 were $5,000 and $5,000, respectively.

Inventories

Inventories are valued at the lower of cost (determined primarily by the average cost method) or net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. As of March 31, 2023 and December 31, 2022, there was no allowance for slow moving or obsolete inventory. The Company periodically assessed its inventory for slow moving and/or obsolete items. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired.

Property and Equipment

Property and Equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:

Furniture and fixtures		5 years
Leasehold improvement		Lesser of lease life or economic life
Equipment		5 years
Computers and software		5 years

Long-Lived Assets

The Company applies the provisions of Accounting Standards Codification (“ASC”) Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at March 31, 2023 and December 31, 2022, the Company believes there was no impairment of its long-lived assets.

Goodwill

Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. The entire goodwill balance in the accompanying financial statements resulted from the Company’s acquisition of Overhoff Technology Corporation in 2006. The Company complies with ASC 350, Goodwill and Other Indefinite Lived Intangible Assets, requiring that a test for impairment be performed at least annually. As of December 31, 2022 the Company performed the required impairment analysis which resulted in no impairment adjustments. Although the Company experienced a significant decline in revenue due to the effects of COVID-19, management expects that it is more likely than not that its revenue and cost of goods sold will be more in-line with pre-COVID-19 levels in upcoming periods. Significant estimates used in the goodwill impairment analysis may change in the upcoming year if revenues do not rebound and cost of materials continue to increase.

Derivative Financial Instruments

The Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. As of March 31, 2023 and December 31, 2022, there are no derivative liabilities associated with our convertible notes payable.

Investments

The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, the Company measures the equity security at fair value as of the date that the observable transaction occurred (“the measurement alternative”) in accordance with ASC 321. The Company accounts for investments for which it owns 20% or more, but less than 50% on the equity method in accordance with ASC 323.

Fair Value of Financial Instruments

For certain of the Company’s financial instruments, including cash, accounts receivable, accounts payable, accrued liabilities, customer deposits, and line of credit, the carrying amounts approximate their fair values due to their short maturities. In addition, the Company has a note payable to shareholder that the carrying amount also approximates fair value.

Revenue Recognition

Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for the Company on January 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606. As sales are and have been primarily from the sale of products to customers, and the Company has no significant post-delivery obligations, this new standard did not result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605, Revenue Recognition.

Revenues from product sales are recognized under Topic 606 in a manner that reasonably reflects the delivery of its products to customers in return for expected consideration and includes the following elements:

●

executed contracts with the Company’s customers that it believes are legally enforceable;

●

identification of performance obligations in the respective contract;

●

determination of the transaction price for each performance obligation in the respective contract;

●

allocation the transaction price to each performance obligation; and

●

recognition of revenue only when the Company satisfies each performance obligation.

These five elements, as applied to each of the Company’s revenue category, is summarized below:

●

Product sales - revenue is recognized when the Company performs its obligations under the contracts it has with its customers to deliver products at an agreed upon price and it is generally when the control of the product has been transferred to the customer.

Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as customer deposits.

Sales returns and allowances was $0 for the three months ended March 31, 2023 and 2022. The Company provides a one-year warranty on all sales. Warranty expense for the three months ended March 31, 2023 and 2022 was insignificant. The Company does not provide unconditional right of return, price protection or any other concessions to its customers.

See Notes 12 and 13 for disclosures of revenue disaggregated by geographical area and product line.

Customer Deposits

Customer deposits represent cash paid to the Company by customers before the product has been completed and shipped.

Income Taxes

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The adoption had no effect on the Company’s consolidated financial statements.

Stock-Based Compensation

The Company records stock-based compensation in accordance with FASB ASC Topic 718, “Compensation – Stock Compensation.” FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee’s requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

Basic and Diluted Earnings Per Share

Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS assumes that all dilutive convertible shares and stock warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. As of March 31, 2023 and December 31, 2022 there were 2,500,000 and 2,500,000 warrants outstanding, respectively, to purchase shares of common stock. The equivalent number of shares to satisfy our convertible debt and warrants at March 31, 2023 is 7,792,366. Basic and diluted earnings per share are the same during the three months ended March 31, 2023 and 2022 due to the net loss incurred.

Segment Reporting

FASB ASC Topic 280, Segment Reporting, requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company determined it has two reportable segments. See Note 12.

Related Parties

The Company accounts for related party transactions in accordance with ASC 850, Related Party Disclosures. A party is considered to be related to the Company if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.

Reclassifications

Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or stockholders’ equity.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 was issued to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new standard represents significant changes to accounting for credit losses. Full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope. The current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold. The expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts. This ASU as amended by ASU 2019-10, is effective for fiscal years beginning after December 15, 2022. The Company has determined that this ASU does not have a material effect on the Company’s consolidated financial statements and related disclosures.

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes which amends ASC 740 Income Taxes (ASC 740). This update is intended to simplify accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and amending existing guidance to improve consistent application of ASC 740. This update is effective for fiscal years beginning after December 15, 2021. The guidance in this update has various elements, some of which are applied on a prospective basis and others on a retrospective basis with earlier application permitted. The Company is currently evaluating the effect of this ASU on the Company’s consolidated financial statements and related disclosures.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock. For convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, the embedded conversion features no longer are separated from the host contract. ASU 2020-06 also removes certain conditions that should be considered in the derivatives scope exception evaluation under Subtopic 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, and clarify the scope and certain requirements under Subtopic 815-40. In addition, ASU 2020-06 improves the guidance related to the disclosures and earnings-per-share (EPS) for convertible instruments and contract in entity’s own equity. ASU 2020-06 is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Board specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluation the impact this ASU will have on its consolidated financial statements.

Note 3 – Inventories

Inventories at March 31, 2023 and December 31, 2022 consisted of the following:

	March 31,		December 31,
	2023		2022
Raw materials	$	1,148,942	$	1,244,880
Work in Progress		409,674		409,637
Finished goods		597,806		370,127
Total inventories	$	2,156,422	$	2,024,664

At March 31, 2023 and December 31, 2022, the inventory reserve was $0.

Note 4 – Property and Equipment

The following are the details of the property and equipment at March 31, 2023 and December 31, 2022:

	March 31,			December 31,
	2023			2022
Furniture and fixtures	$	148,033		$	148,033
Leasehold Improvements		50,091			50,091
Equipment		237,418			237,418
Computers and software		39,482			39,482
		475,024			475,024
Less accumulated depreciation		(469,810	)		(468,523	)
Property and equipment, net	$	5,214		$	6,501

Depreciation expense for the three months ended March 31, 2023 and 2022 was $1,287 and $3,218 respectively. At March 31, 2023, the Company has $440,628 of fully depreciated property and equipment that is still in use.

Note 5 – Investments

MIFTEC

On August 3, 2018, the Company closed an agreement by and among, MIFTEC Laboratories, Inc. (“MIFTEC”), a licensee of Magneto-Inertial Fusion Technologies, Inc., (“MIFTI”), and the Company. MIFTEC is a licensee of MIFTI radionuclide technology. MIFTEC will engage the Company to manufacture equipment pursuant to MIFTEC’s specifications and designs and have the Company as a sales representative for the manufactured equipment. The Company will be the exclusive manufacturer and supplier to MIFTEC of equipment in North America and Asia. In addition, the Company received a 10% ownership interest in MIFTEC. The consideration for the exclusive manufacturing rights and a 10% ownership interest in MIFTEC was $500,000 and 300,000 shares of the Company’s common stock valued at $594,000. The fair value was determined based on the Company’s stock price on August 3, 2018. The Company recorded the value of the 10% interest in MIFTEC at $10,000 and recorded $1,084,000 as the acquisition of manufacturing and supply rights in the accompanying consolidated statement of operations during the year ended December 31, 2018. The Company evaluated this investment for impairment and determined that an impairment of $9,000 was necessary during the year ended December 31, 2019. The carrying value of this investment at March 31, 2023 and December 31, 2022 was $1,000 and $1,000, respectively.

MIFTI

In April 2019, the Company also entered into a Cooperative Agreement with MIFTI whereby the Company acquired certain exclusive manufacturing and supply rights, including thermonuclear fusion-powered reactor for production of electricity per MIFTI designs in return for $500,000, of which $100,000 is payable upon signing, $200,000 within four months of the agreement and $200,000 within nine months of the agreement. The $500,000 is an option to buy a 10% interest in MIFTI for $2,700,000, if completed with 24 months of the agreement date. If the options expire, MIFTI shall issue the Company 500,000 shares of common stock and rescind all other exclusive rights contained in the agreement. The option was rescinded and the Company received 500,000 shares of MIFTI common stock which represents an ownership of approximately 0.56% for its $500,000 investment. The Company evaluated this investment for impairment and determined that an impairment of $499,000 was necessary during the year ended December 31, 2019. The carrying value of this investment at March 31, 2023 and December 31, 2022 was $1,000 and $1,000, respectively.

Grapheton

On February 5, 2020, the Company entered into a Stock Purchase Agreement (“SPA”) with Grapheton, Inc., a California corporation (“Grapheton”). The transaction was closed on March 12, 2020. Grapheton is a start-up company that focuses on building energy storage devises, known as supercapacitors, from a new material system. The technology utilized by Grapheton has been proven to provide a compelling advantage in microelectrode arrays with superior electrical and electrochemical properties.

Pursuant to the terms of the SPA, the Corporation will acquire a total of 2,552 shares of Grapheton’s common stock over a two-year period. At closing, the Company was issued at total of 1,452 shares of Grapheton’s common stock for $235,000 and 858,896 shares of the Company’s common stock valued at $601,227.

In connection with the SPA, during the second quarter of 2021 the Company received an additional 1,100 shares of Grapheton’s common stock in exchange for the Company’s issuing an additional 1,121,071 shares of common stock valued at 633,405. In addition, Grapheton fulfilled its requirements under the earn out provision and the Company is obligated to make the first earn out payment of $192,500. This amount is recorded as accrued expense in the accompanying consolidated balance sheet.

An additional “true up” issuance of the Company’s common stock to Grapheton may be made on the second anniversary of the closing of the SPA, based on the valuation of the Company’s common stock on that date by a third-party valuator.

The Company currently owns 35.8% of Grapheton and accounts for its investment in Grapheton using the equity method of accounting is accordance with ASC 323. The Company evaluated this investment and recorded a loss attributed to equity investment of $8,059 during the three months ended March 31, 2023 and $0 during the three months ended March 31, 2022.

Information regarding Grapheton as of and for the three months ended March 31, 2023 is below:

Current assets	$	8,126
Total assets		13,501
Current liabilities		748,333
Total liabilities		748,333
Total stockholders’ deficiency	$	(722,082	)

Revenue	$	-
Operating expenses		167,190
Other expenses		-
Net loss	$	167,190

Averox

On March 3, 2023, the Company divested itself of its wholly owned subsidiary, Cali From Above, through a Membership Interest Purchase Agreement with the Company’s President and Chief Executive Officer, Robert Goldstein. Consideration received by the Company was 65,000,000 shares of Averox, Inc. (OTC:AVRI), resulting in the Company owning 26% of the issued and outstanding shares of common stock of AVRI. The Company and Cali From Above also signed a Cooperation Agreement whereby the Company holds exclusive sourcing and manufacturing rights for Cali From Above products, thus making Cali From Above a new customer of the Company. The Company accounts for its investment in Averox using the equity method of accounting in accordance with ASC 323. See Note 15.

Note 6 – Notes Payable

In connection with the acquisition of assets from ECC, the Company issued a note payable to the owner of ECC. The note accrued interest at 5% per annum, requires quarterly principal and interest payments of $4,518 and is due on April 15, 2021. At March 31, 2023 and December 31, 2022, the amount outstanding under this note payable was $5,272 and $5,272, respectively. The Company repaid $0 during the three months ended March 31, 2023.

On December 26, 2020, a line of credit held by the company had matured, and based on the terms of the line of credit agreement was converted to a note payable upon demand. The obligation accrues interest at the rate of $10.89 per day until the bank receives full payment. As of March 31, 2023, the balance owed by the Company was $0.

On May 5, 2022, the Company received a loan in connection with the issuance of stock warrants in the amount of $750,000. The loan has terms of 12 months and accrues interest at 5% per annum. As part of the issuance of the loan, the company identified debt discounts related to the warrants issued, the incentive shares issued as discussed at Note 10, the beneficial conversion feature of the debt, and the expenses paid as part of the issuance. The total debt discounts recorded as of the date of the note was $550,538. At March 31, 2023 and pursuant to the down-round provision of the note and associated warrants, the Company reevaluated the beneficial conversion feature which resulted in additional debt discount recorded of $24,558. The total remaining unamortized debt discount on this note at March 31, 2023 is $116,951.

On October 10, 2022, the Company received a loan in connection with the issuance of stock warrants in the amount of $375,000. The loan has terms of 12 months and accrues interest at 5% per annum. As part of the issuance of the loan, the company identified debt discounts related to the warrants issued, the beneficial conversion feature of the debt, and the expenses paid as part of the issuance. The total debt discounts recorded as of the date of the note was $200,488. At March 31, 2023 and pursuant to the down-round provision of the note and associated warrants, the Company reevaluated the beneficial conversion feature recorded which resulted in additional debt discount recorded of $97,973. The total remaining unamortized debt discount on this note at March 31, 2023 is $207,912.

The total debt discount amortization recorded on the Company’s notes for the three months ended March 31, 2023 was $331,559.

Future maturities of all notes payable, net of any debt discounts as of March 31, 2023, are as follows:

Years ended December 31,
2023	$	510,135
2024		-
2025		-
2026		-
2027		-
Thereafter		-
	$	510,135

Note 7 – Note Payable to Shareholder

Robert Goldstein, the CEO and majority shareholder, has loaned funds to the Company from time to time to cover general operating expenses. These loans are evidenced by unsecured, non-interest-bearing notes, payable upon demand. During the three months ended March 31, 2023, the Company’s majority shareholder loaned an additional $42,300 to the Company. The amounts due to Mr. Goldstein are $916,979 and $874,679 as of March 31, 2023 and December 31, 2022, respectively.

Note 8 – Line of Credit

As of March 31, 2023, the Company had four lines of credit with a maximum borrowing amount of $400,000 with interest ranging from 5.5% to 11.5% and are unsecured. As of March 31, 2023 and December 31, 2022, the amounts outstanding under these lines of credit were $307,937 and $307,321, respectively.

Note 9 – Leases

The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company must discount lease payments based on an estimate of its incremental borrowing rate which is based on the interest rate of similar debt outstanding.

The Company leases its current facilities from Gold Team Inc., a company owned by the Company’s CEO, which owns both the Canoga Park, CA and Milford, Ohio locations. The leases expired on April 30, 2020 and the Company exercised its renewal option for an additional 12 months. The new lease is not more than 12 months; therefore, the disclosures under ASC 842 are not required. Future minimum lease payments under this agreement for the twelve months ending December 31, 2022 is $168,000. Effective January 1, 2019, the Company adopted the provision of ASC 842 Leases.

The lease expense for the three months ended March 31, 2023 and 2022 was $42,000 and $42,000, respectively. The cash paid under operating leases during the three months ended March 31, 2023 and 2022 was $0 and $0, respectively. At March 31, 2023, the weighted average remaining lease terms were 0.1 years and the weighted average discount rate was 8%.

Note 10 – Commitments and Contingencies

From time to time the Company may be a party to litigation matters involving claims against the Company. Management believes that there are no known or potential matters that would have a material effect on the Company’s financial position or results of operations.

Note 11 – Shareholders’ Equity

Common Stock

During the three months ended March 31, 2023, the Company issued:

●

1,500,000 shares of common stock to its Directors and President, valued at $175,500;

●

800,000 shares of common stock valued at $120,000 in satisfaction of convertible debt and interest;

●

375,000 shares of common stock to consultants for services rendered valued at $48,850. The fair value was determined based on the Company’s stock price on the grant date; and

During the three months ended March 31, 2022, the Company issued:

●

75,000 shares of common stock to consultants for services rendered valued at $22,500. The fair value was determined based on the Company’s stock price on the grant date;

Warrants

The following table summarizes the activity related to warrants:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Warrants		Exercise		Contractual		Intrinsic
	Outstanding		Price		Life		Value
Outstanding, December 31, 2022		2,500,000	$	0.11		2.32	$	-
Granted		-		-		-
Forfeited		-
Exercised		-
Outstanding, March 31, 2023		2,500,000	$	0.11		2.32	$	-
Exercisable, March 31, 2023		2,500,000	$	0.11		2.32	$	-

The above warrants contain a down round provision that requires the exercise price to be adjusted if the Company sells shares of common stock below the current exercise price. During the three months ended March 31, 2023, the Company issued shares of common stock for $0.11 therefore, the exercise price of these warrants was adjusted from $0.14 to $0.11. The change in fair value between the value of the warrants using the new exercise price versus the old exercise price was calculated to be $2,013. This amount is recorded as a deemed dividend in the accompanying consolidated financial statements during the three months ended March 31, 2023.

The following table summarizes information about warrants outstanding and exercisable as of March 31, 2023:

Note 12 – Segment Reporting

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has two reportable segments: Optron and Overhoff. Optron is located in Canoga Park, California and Overhoff is located in Milford, Ohio. The assets and operations of the Company’s recent acquisition of the assets of Electronic Control Concepts are included with Overhoff in the table below. The assets and operations of the Company’s subsidiary, Cali From Above, are through March 3, 2023, which is the date the Company divested its interest in Cali and are included with Optron in the table below.

The following tables summarize the Company’s segment information for the three months ended March 31, 2023 and 2022:

	March 31,
	2023			2022

Sales
Optron	$	243,333		$	56,994
Overhoff		404,373			282,521
Corporate		-			-
	$	647,706		$	339,315

Gross profit
Optron	$	158,520		$	44,082
Overhoff		277,069			183,195
Corporate		-			-
	$	435,589		$	227,277

(Loss)/gain from operations
Optron	$	(53,973	)	$	(218,838	)
Overhoff		36,987			(306,352	)
Corporate		(283,250	)		(121,036	)
	$	(300,236	)	$	(646,226	)

Interest Expenses
Optron	$	5,272		$	2,445
Overhoff		3,656			972
Corporate		13,212			-
	$	22,140		$	3,417

Net income/(loss)
Optron	$	(66,785	)	$	(215,283	)
Overhoff		38,331			(316,324	)
Corporate		(636,080	)		(118,036	)
	$	(664,534	)	$	(649,643	)

	As of March 31, 2023		As of December 31, 2022
Total Assets
Optron	$	1,115,267	$	1,021,817
Overhoff		2,009,915		2,037,988
Corporate		38,783		48,932
	$	3,163,965	$	3,108,737

Goodwill
Optron	$	-	$	-
Overhoff		570,176		570,176
Corporate		-		-
	$	570,176	$	570,176

Note 13 – Geographical Sales

The geographical distribution of the Company’s sales for the three months ended March 31, 2023 and 2022 is as follows:

	Three Months Ended March 31,
	2023		2022
Geographical sales
North America	$	635,612	$	517,230
Asia		7,915		39,040
Other		4,179		127,501
	$	647,706	$	683,771

Note 14 – Related Party Transactions

The Company leases its current facilities from Gold Team Inc., a company owned by the Company’s CEO, which owns both the Canoga Park, CA and Milford, Ohio locations. Rent expense for the three months ended March 31, 2023 and 2022 was $42,000 and $42,000, respectively. As of March 31, 2023 and December 31, 2022, amounts payable to Gold Team Inc. in connection with the above leases amount to $322,000 and $280,000, respectively (See Note 9). The lease expired on April 30, 2021 and is currently on a month-to-month basis.

In addition, as of March 31, 2023 and December 31, 2022, the Company had accrued compensation payable to its majority shareholder of $575,000 and $550,000, respectively.

Also see Note 7.

Note 15 – Deconsolidation of Subsidiary

On March 3, 2023, the Company divested itself of its wholly-owned subsidiary, Cali From Above, through a Membership Interest Purchase Agreement with the Company’s President and Chief Executive Officer, Robert Goldstein. Consideration received by the Company was 65,000,000 shares of Averox, Inc. (OTC:AVRI), resulting in the Company owning 26% of the issued and outstanding shares of common stock of AVRI. The Company considered the guidance under ASC 810-10-40 in determining the accounting treatment for the transaction and it was determined that the fair value of the 65,000,000 shares received on March 3, 2023 was $2,539, which was the fair value of the assets transferred upon deconsolidation by the Company. Additionally, this method was used due to there being no active trading by Averox on the date of the transaction. Also at closing, the Company and Cali From Above signed a Cooperation Agreement whereby the Company holds exclusive sourcing and manufacturing rights for Cali From Above products, thus making Cali From Above a new customer of the Company.

Upon deconsolidation, the Company recorded a loss of $2,539, reflecting the value of $2,539 in cash in Cali From Above.

Note 16 – Concentrations

Two customers accounted for 44% and 24% of the Company’s sales for the three months ended March 31, 2023 and one customer accounted for 45.8% of the Company’s sales for the three months ended March 31, 2022.

No vendors accounted for more than 10% of the Company’s purchases for the three months ended March 31, 2023 and 2022.

Note 17 – Subsequent Events

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date the financial statements were available to be issued and has determined that no material subsequent events exist other than the following:

On April 11, 2023, the Company issued 771,845 shares of common stock, by cashless exercise, pursuant to a Warrant Agreement associated with a convertible note payable entered into on May 5, 2022.

On April 26, 2023, the Company issued 420,000 shares to Howard Isaacs in connection with investor relations services provided by the consultant.

On April 26, 2023, the Company issued 50,000 shares to Richard Cavalli in connection with investor relations services provided by the consultant.

On May 25, 2023, the Company issued 517,391 shares of common stock, by cashless exercise, pursuant to a Warrant Agreement associated with a convertible note payable entered into on May 5, 2022.

On June 12, 2023, the Company issued 75,000 shares to Prashant Mehta in connection with the consulting services agreement entered into, by and between US Nuclear Corp and Prashant Mehta.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand US Nuclear Corp, our operations and our present business environment. MD&A is provided as a supplement to—and should be read in conjunction with—our consolidated financial statements and the accompanying notes included in this Quarterly Report on Form 10-Q. The audited financial statements for our fiscal year ended December 31, 2022 filed with the Securities Exchange Commission on Form 10-K on May 12, 2023 should be read in conjunction with the discussion below. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results may differ materially from those anticipated in these forward-looking statements. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in these unaudited financial statements.

We were incorporated in Delaware on February 14, 2012, and on March 2, 2012, we filed a registration statement on Form 10 to register with the U.S. Securities and Exchange Commission as a public company. We were originally organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation.

Since our acquisition of Overhoff Technology in 2006, we have had discussions with other companies in our industry for an acquisition. While we targeted Overhoff due to its unique position in the tritium market, we had not commenced an acquisition since our Overhoff Technology acquisition; we believe in part the reason was due to lack of additional capital, our status as a privately-held entity at the time, and focus on developing our own products. We will seek out companies whom our management believes will provide value to our customers and will complement our business. We will focus on diversifying our product line into a larger range so that our customers and vendors may have a more expansive experience in type, choice, options, price and selection. We also believe that with a more diverse product line we will become more competitive as our industry is intensely competitive.

Generally, our product concentration places a heavy reliance on our Overhoff Technology division. In 2022, we derived 55.9% of our total revenues from sales made by Overhoff to two customers. We expect to encounter a continuation of this trend unless we are successful in diversifying our client base, executing our acquisition strategy and experience increases in business from our Technical Associates division.

Our international revenues were 26.57% of our total revenue in 2022. We expect this to increase over time as we continue to field new orders inquires and engage new customers overseas and recover post-pandemic. We believe that South Korea and China will likely be a larger contributor to revenue within the next few years. While we maintain steady growth domestically, the international side of our business may be a larger component as nuclear technology and rapid development for clean energy grows abroad. Additionally, the Company relies on continued growth and orders from CANDU reactors (Canada Deuterium Uranium), and rapid development of the next generation of nuclear reactors called Molten Salt Reactors, (MSR) and Liquid-Fluoride Thorium Reactors (LFTR), all of which purchase tritium detection and monitor products. There can be no assurances as to our growth projections and our risk profile as we depend upon increased foreign customers for business.

For the next twelve months, we anticipate we will need approximately $5,000,000 in additional capital to fund our business plans. If we do not raise the required capital, we may not meet our expenses and there can be no assurance that we will be able to do so and if we do, we may find the cost of such financing to be burdensome on the Company. Additionally, we may not be able to execute on our business plans due to unforeseen market forces such as lower natural gas prices, difficulty attracting qualified executive staff, general downturn in our sector or by competition as we operate in an extremely competitive market for all of our product offerings.

Robert I. Goldstein, our President, Chief Executive Officer and Chairman of the Board of Directors also maintains a position as President of Gold Team Inc., a Delaware company that invests in industrial real estate properties for investment purposes. He holds an 8% interest in Gold Team Inc. and spends approximately 5 hours per week with affairs related to Gold Team Inc. The Company leases its current facilities from Gold Team Inc. which owns both the Canoga Park, CA and Milford, Ohio properties at an expense of $7,000 for each facility per month.

On May 31, 2016, we entered into an Asset Purchase Agreement with Electronic Control Concepts (“ECC”) whereby the Company purchased certain tangible and intangible assets of ECC. ECC a small manufacturer of test and maintenance meters for x-ray machines both medical and industrial. We acquired ECC to give a boost to our current x-ray related product and hospital/medical product sales.

Results of Operations

For the three months ended March 31, 2023 compared to the three months ended March 31, 2022:

	Three Months Ended March 31,						Change
	2023			2022			$			%

Sales	$	647,706		$	339,515		$	322,191			48.69	%
Cost of goods sold		212,117			112,238			99,879			47.09	%
Gross profit		435,589			227,277			222,312			49.45	%
Selling, general and administrative expenses		735,825			873,503			(123,678	)		-16.49	%
Loss from operations		(300,236	)		(646,226	)		345,990			115.24	%
Other income (expense)		(364,298	)		(3,417	)		(314,770	)		98.93	%
Loss before provision for income taxes		(664,534	)		(649,643	)		31,220			-5.05	%
Provision for income taxes		-			-			-
Net loss	$	(664,534	)	$	(649,643	)	$	31,220			-5.05	%

Sales for the three months ended March 31, 2023 were $647,706 compared to $339,515 for the same period in 2022. The increase of $308,191 or 47.58% is a result of an increase in sales from our Overhoff subsidiary of $124,012 and an increase in sales from our Optron subsidiary of $184,179. The overall increase in sales is principally due to recovering from the impact of COVID-19. The sales breakdown for the three months ended March 31, 2023 is as follows:

North America 98.17%

Asia (Including Japan) 1.20%

Other .63%

Our gross margins for the three months ended March 31, 2023 were 67.2% as compared to 66.9% for the same period in 2022. Gross margins increased by 0.31% for the three months ended March 31, 2023 due to fluctuations in the cost of materials used in manufacturing our products.

Selling, general and administrative expense for the three months ended March 31, 2023 were $735,825 compared to $873,503 for the same period in 2022. The decrease of $137,678 or 18.71% was principally due to decreases in professional fees, payroll and employee benefits, and advertising and marketing expense, offset by an increase in stock-based compensation. The overall decrease in these operating expenses is a result of management’s continued efforts in closely monitoring overhead and expenses and negotiating better pricing with its vendors and consultants. During the three months ended March 31, 2023, stock-based compensation was $234,100 compared to $62,526 during the same period in 2022. Stock based compensation is issued as incentives to consultants to increase revenues through the acquisition of new customers.

Other expense for the three months ended March 31, 2023 was $364,298, an increase of $360,881 from other expense of $3,417 for the same period in 2022. The increase was due to an increase in the amortization of debt discounts associated with convertible debentures of $331,559, interest expense of $22,140, a $2,539 loss on the deconsolidation of Cali From Above, and a $8,059 loss on equity in our investment with Grapheton.

Net loss for the three months ended March 31, 2023 was $664,534 compared to $649,643 for the same period in 2022. The change was principally attributed to the factors described above.

Liquidity and Capital Resources

Our operations have historically been financed by our majority shareholder and more recently from proceeds from the sale of our common stock. As funds were needed for working capital purposes, our majority shareholder would loan us the needed funds. We anticipate funding the growth of our business through the sales of additional shares of our common stock and loans from our majority stockholder if necessary.

At March 31, 2023, total assets increased by 1.75% to $3,163,965 from $3,108,737 at December 31, 2022. The increase primarily reflects an increase in inventory, an increase in cash, a note receivable recorded during the period, offset by decreases in accounts receivable and the carrying value of investments held by the Company.

At March 31, 2023, total liabilities increased by 6,75% to $3,707,383 from $3,457,041 at December 31, 2022. The increase is principally related to an increase in accrued liabilities, notes payable, and accrued compensation to officers.

Net cash provided by/(used in) operating activities for the three months ended March 31, 2023 was $66,052 compared to ($338,864) for the same period in 2022. The change in cash from operations was principally due to changes in working capital accounts.

Net cash used in investing activities for the three months ended March 31, 2023 was $16,539 compared to $12,629 for the same period in 2022. The increase in cash used investing activities was due to a decrease of $12,629 in the purchase of property and equipment offset by an increase related to a $14,000 note payable and cash of $2,539 surrendered in the deconsolidation of Cali From Above during the period.

Net cash provided by financing activities for the three months ended March 31, 2023 was $38,614 compared to $171,031 for the same period in 2022. The change in cash from financing activities was primarily due to a decrease in proceeds from shareholder loans.

Critical Accounting Policies

Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States (“US GAAP”). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenues and expenses amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

We believe the following is among the most critical accounting policies that impact our consolidated financial statements. We suggest that our significant accounting policies, as described in our financial statements in the Summary of Significant Accounting Policies, be read in conjunction with this Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Income Taxes

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

None

Item 4. Controls and Procedures.

Evaluation of disclosure controls and procedures

Under the supervision and with the participation of our management, including our principal executive officer and the principal financial officer, we are responsible for conducting an evaluation of the effectiveness of the design and operation of our internal controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as of the end of the fiscal quarter covered by this report. Disclosure controls and procedures means that the material information required to be included in our Securities and Exchange Commission (“SEC”) reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms relating to our company, particularly during the period when this report was being prepared. Based on this evaluation, our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were not effective as of March 31, 2023.

Changes in internal controls

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, performed an evaluation to determine whether any change in our internal controls over financial reporting occurred during the three-month period ended March 31, 2023. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that no change occurred in the Company’s internal controls over financial reporting during the three months ended March 31, 2023 that has materially affected, or is reasonably likely to materially affect, the Company’s internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

There are not presently any material pending legal proceedings to which the Company is a party or as to which any of its property is subject, and no such proceedings are known to the Company to be threatened or contemplated against it.

Item 1A. Risk Factors

See our Form 10K filed on May 12, 2023 for Risk Factors.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the year ending December 31, 2022, the Company issued 400,000 shares of common stock to Prashant Mehta in connection with the consulting services agreement entered into, by and between US Nuclear Corp and Prashant Mehta.

During the year ending December 31, 2022, the Company issued 625,000 shares of common stock in in relation to debt that was obtained.

During the year ending December 31, 2022, the Company issued 1,600,000 shares of common stock in satisfaction of principle, interest, and fees on a Convertible Note held by a third party.

During the year ending December 31, 2022, the Company issued 203,027 shares of common stock to Carter Terry & Co. in connection with investor relations services provided by the consultant.

During the year ending December 31, 2022, the Company issued 40,000 shares of common stock to Richard Cavalli in connection with investor relations services provided by the consultant.

During the year ending December 31, 2022, the Company issued 200,000 shares of common stock to Howard Isaacs in connection with investor relations services provided by the consultant.

On January 9, 2023, the Company issued 100,000 shares to Prashant Mehta in connection with the consulting services agreement entered into, by and between US Nuclear Corp and Prashant Mehta.

On January 19, 2023, the Company issued 400,000 shares of common stock in satisfaction of principle, interest, and fees on a Convertible Note held by a third party.

On January 23, 2023, the Company issued 50,000 shares of common stock to Richard Cavalli in connection with investor relations services provided by the consultant.

On January 23, 2023, the Company issued 210,000 shares of common stock to Howard Isaacs in connection with investor relations services provided by the consultant.

On February 23, 2023, the Company issued 400,000 shares of common stock in satisfaction of principle, interest, and fees on a Convertible Note held by a third party.

On February 24, 2023, the Company issued 200,000 shares to Prashant Mehta in connection with the consulting services agreement entered into, by and between US Nuclear Corp and Prashant Mehta.

On March 14, 2023, the Company issued an aggregate of 1,500,000 shares to two Directors and its Chief Executive Officer as compensation for services provided to the Company.

On March 14, 2023, the Company issued 75,000 shares to Prashant Mehta in connection with the consulting services agreement entered into, by and between US Nuclear Corp and Prashant Mehta.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Incorporated by reference

Exhibit

Exhibit Description

Filed
herewith

Form

Period
ending

Exhibit

Filing date

3.1

Certificate of Incorporation

3.1

03/02/2012

3.2

By-Laws

3.2

03/02/2012

3.3

Amendment to Certificate of Incorporation

8-K

3.3

05/29/2012

4.1

Specimen Stock Certificate

4.1

03/02/2012

10.1

Robert I. Goldstein Employment Agreement

10-Q

10.1

11/11/2014

10.2

Forgiveness of Debt and Conversion Agreement

10-Q

10.2

11/11/2014

31.1

Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.2

Certification pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

101.INS

Inline XBRL Instance Document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	US Nuclear Corp

	By:	/s/ Robert Goldstein
		President, Chief Executive Officer, Chairman of the Board of Directors

	By:	/s/ Richard Landry
		Chief Financial Officer and Secretary

Date: June 27, 2023

28428215 32634839 0.02 0.02 false --12-31 Q1 0001543623 US NUCLEAR CORP. 0001543623 2023-01-01 2023-03-31 0001543623 2023-06-27 0001543623 2023-03-31 0001543623 2022-12-31 0001543623 2022-01-01 2022-03-31 0001543623 us-gaap:CommonStockMember 2022-12-31 0001543623 ucle:CommonSharesToBeIssuedMember 2022-12-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001543623 us-gaap:RetainedEarningsMember 2022-12-31 0001543623 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001543623 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001543623 ucle:CommonSharesToBeIssuedMember 2023-01-01 2023-03-31 0001543623 us-gaap:CommonStockMember 2023-03-31 0001543623 ucle:CommonSharesToBeIssuedMember 2023-03-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001543623 us-gaap:RetainedEarningsMember 2023-03-31 0001543623 us-gaap:CommonStockMember 2021-12-31 0001543623 ucle:CommonSharesToBeIssuedMember 2021-12-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001543623 us-gaap:RetainedEarningsMember 2021-12-31 0001543623 2021-12-31 0001543623 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001543623 ucle:CommonSharesToBeIssuedMember 2022-01-01 2022-03-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001543623 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001543623 us-gaap:CommonStockMember 2022-03-31 0001543623 ucle:CommonSharesToBeIssuedMember 2022-03-31 0001543623 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001543623 us-gaap:RetainedEarningsMember 2022-03-31 0001543623 2022-03-31 0001543623 us-gaap:FurnitureAndFixturesMember 2023-01-01 2023-03-31 0001543623 us-gaap:LeaseholdImprovementsMember 2023-01-01 2023-03-31 0001543623 us-gaap:EquipmentMember 2023-01-01 2023-03-31 0001543623 us-gaap:ComputerEquipmentMember 2023-01-01 2023-03-31 0001543623 us-gaap:FurnitureAndFixturesMember 2023-03-31 0001543623 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001543623 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001543623 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001543623 us-gaap:EquipmentMember 2023-03-31 0001543623 us-gaap:EquipmentMember 2022-12-31 0001543623 us-gaap:ComputerEquipmentMember 2023-03-31 0001543623 us-gaap:ComputerEquipmentMember 2022-12-31 0001543623 2018-08-03 0001543623 ucle:OwnershipInterestMember ucle:MIFTECMember 2018-08-03 0001543623 ucle:MIFTECMember 2018-08-03 0001543623 ucle:MIFTECMember 2018-08-01 2018-08-03 0001543623 ucle:MIFTECMember 2018-12-31 0001543623 ucle:MIFTECMember 2018-01-01 2018-12-31 0001543623 ucle:MIFTECMember 2019-01-01 2019-12-31 0001543623 ucle:MIFTECMember 2023-01-01 2023-03-31 0001543623 ucle:MIFTECMember 2022-01-01 2022-12-31 0001543623 ucle:MIFTIMember 2019-04-01 2019-04-30 0001543623 ucle:MIFTIMember 2019-04-30 0001543623 2019-04-30 0001543623 ucle:MIFTIMember 2019-01-01 2019-12-31 0001543623 ucle:MIFTIMember 2023-01-01 2023-03-31 0001543623 ucle:MIFTIMember 2022-01-01 2022-12-31 0001543623 ucle:GraphetonMember 2023-03-31 0001543623 2021-04-01 2021-06-30 0001543623 ucle:GraphetonMember 2021-04-01 2021-06-30 0001543623 2023-03-01 2023-03-03 0001543623 ucle:EquityMethodInvestmentsOwnershipPercentageMember 2023-03-03 0001543623 ucle:GraphetonMember 2023-03-31 0001543623 ucle:GraphetonMember 2023-01-01 2023-03-31 0001543623 2021-04-01 2021-04-15 0001543623 2020-12-01 2020-12-26 0001543623 2022-05-01 2022-05-05 0001543623 2022-05-05 0001543623 2022-10-01 2022-10-10 0001543623 2022-10-10 0001543623 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001543623 ucle:MrGoldsteinMember 2023-03-31 0001543623 ucle:MrGoldsteinMember 2022-12-31 0001543623 us-gaap:LineOfCreditMember 2023-03-31 0001543623 srt:MinimumMember us-gaap:LineOfCreditMember 2023-03-31 0001543623 srt:MaximumMember us-gaap:LineOfCreditMember 2023-03-31 0001543623 2022-01-01 2022-12-31 0001543623 us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0001543623 ucle:ConsultantsMember 2023-01-01 2023-03-31 0001543623 srt:MinimumMember 2023-01-01 2023-03-31 0001543623 us-gaap:WarrantMember 2022-12-31 0001543623 us-gaap:WarrantMember 2023-03-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OptronMember 2023-01-01 2023-03-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OptronMember 2022-01-01 2022-03-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OverhoffMember 2023-01-01 2023-03-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OverhoffMember 2022-01-01 2022-03-31 0001543623 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2023-01-01 2023-03-31 0001543623 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2022-01-01 2022-03-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OptronMember 2023-03-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OptronMember 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OverhoffMember 2023-03-31 0001543623 us-gaap:OperatingSegmentsMember ucle:OverhoffMember 2022-12-31 0001543623 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2023-03-31 0001543623 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2022-12-31 0001543623 srt:NorthAmericaMember 2023-01-01 2023-03-31 0001543623 srt:NorthAmericaMember 2022-01-01 2022-03-31 0001543623 srt:AsiaMember 2023-01-01 2023-03-31 0001543623 srt:AsiaMember 2022-01-01 2022-03-31 0001543623 ucle:OtherMember 2023-01-01 2023-03-31 0001543623 ucle:OtherMember 2022-01-01 2022-03-31 0001543623 ucle:GoldTeamIncMember 2023-03-31 0001543623 ucle:GoldTeamIncMember 2022-12-31 0001543623 ucle:AveroxIncMember 2023-03-03 2023-03-03 0001543623 ucle:AveroxIncMember 2023-03-03 0001543623 ucle:CustomersOneMember us-gaap:SalesMember 2023-01-01 2023-03-31 0001543623 ucle:CustomersTwoMember us-gaap:SalesMember 2023-01-01 2023-03-31 0001543623 ucle:CustomersOneMember us-gaap:SalesMember 2022-01-01 2022-03-31 0001543623 ucle:PurchaseMember 2023-01-01 2023-03-31 0001543623 ucle:PurchaseMember 2022-01-01 2022-03-31 0001543623 us-gaap:SubsequentEventMember 2023-04-11 0001543623 ucle:HowardIsaacsMember us-gaap:SubsequentEventMember 2023-04-26 0001543623 ucle:RichardCavalliMember us-gaap:SubsequentEventMember 2023-04-26 0001543623 srt:ScenarioForecastMember 2023-05-25 0001543623 srt:ScenarioForecastMember 2023-06-12 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Exhibit 31.1

US Nuclear Corp.

OFFICER’S CERTIFICATE PURSUANT TO SECTION 302

I, Robert I. Goldstein, certify that:

1. I have reviewed this annual report on Form 10-Q for the year ended March 31, 2023 (the “report”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: June 27, 2023

By:	/s/ Robert I. Goldstein
	Robert I. Goldstein
	President, Chief Executive Officer, Chairman
	(Principal Executive Officer)

Exhibit 31.2

US Nuclear Corp.

OFFICER’S CERTIFICATE PURSUANT TO SECTION 302

I, Richard Landry, certify that:

1. I have reviewed this annual report on Form 10-Q for the year ended March 31, 2023 (the “report”);

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: June 27, 2023

By:	/s/ Richard Landry
	Richard Landry
	Chief Financial Officer
	(Principal Executive Officer)

Exhibit 32.1

US Nuclear Corp.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of US Nuclear Corp. (the Registrant) on Form 10-Q for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Robert I. Goldstein, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to Robert I. Goldstein and will be retained by US Nuclear Corp. and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: June 27, 2023

By:	/s/ Robert I. Goldstein
	Robert I. Goldstein
	President, Chief Executive Officer, Chairman
	(Principal Executive Officer)

Exhibit 32.2

US Nuclear Corp.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of US Nuclear Corp. (the Registrant) on Form 10-Q for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Richard Landry, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to Richard Landry and will be retained by US Nuclear Corp. and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: June 27, 2023

By:	/s/ Richard Landry
	Richard Landry
	Chief Financial Officer
	(Principal Executive Officer)

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2023	Jun. 27, 2023
Document Information Line Items
Entity Registrant Name	US NUCLEAR CORP.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		36,390,478
Amendment Flag	false
Entity Central Index Key	0001543623
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-54617
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-4535739
Entity Address, Address Line One	7051 Eton Avenue
Entity Address, City or Town	Canoga Park
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91303
City Area Code	(818)
Local Phone Number	883-7043
Entity Interactive Data Current	Yes

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash	$ 214,236	$ 126,109
Accounts receivable, net	184,378	329,858
Note receivable	14,000
Inventories	2,156,422	2,024,664
Prepaid expenses and other current assets		26,370
TOTAL CURRENT ASSETS	2,569,036	2,507,001
Property and equipment, net	5,214	6,501
Investments	4,539	10,059
Acquisition deposit	15,000	15,000
Goodwill	570,176	570,176
TOTAL ASSETS	3,163,965	3,108,737
CURRENT LIABILITIES
Accounts payable	61,313	100,398
Accounts payable - related party	322,000	280,000
Accrued liabilities	750,053	688,422
Accrued compensation - officers	740,000	695,000
Customer deposit	93,694	88,694
Notes payable	5,272	9,574
Convertible debt, net of debt discount	510,135	412,953
Note payable to shareholder	916,979	874,679
Line of credit	307,937	307,321
TOTAL CURRENT LIABILITIES	3,707,383	3,457,041
TOTAL LIABILITIES	3,707,383	3,457,041
SHAREHOLDERS’ EQUITY:
Common stock, $0.0001 par value; 100,000,000 shares authorized, 34,556,242 and 31,621,242 shares issued and outstanding	3,456	3,162
Common shares to be issued		39,000
Additional paid in capital	15,250,540	14,740,401
Accumulated deficit	(15,797,414)	(15,130,867)
TOTAL SHAREHOLDERS’ EQUITY	(543,418)	(348,304)
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 3,163,965	$ 3,108,737

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	34,556,242	31,621,242
Common stock, shares outstanding	34,556,242	31,621,242

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Sales	$ 647,706	$ 339,515
Cost of sales	212,117	112,238
Gross profit	435,589	227,277
Operating expenses
Selling, general and administrative expenses	735,825	873,503
Total operating expenses	735,825	873,503
Loss from operations	(300,236)	(646,226)
Other income (expense)
Interest expense	(22,140)	(3,417)
Equity loss in investment	(8,059)
Loss on deconsolidation	(2,539)
Amortization of debt discount	(331,559)
Total other income (expense)	(364,298)	(3,417)
Loss before provision for income taxes	(664,534)	(649,643)
Provision for income taxes
Net loss	(664,534)	(649,643)
Deemed dividend for down-round provision in warrants	(2,013)
Net loss attributed to common stockholders	$ (666,547)	$ (649,643)
Weighted average shares outstanding - basic and diluted (in Shares)	32,634,839	28,428,215
Loss per shares - basic and diluted (in Dollars per share)	$ (0.02)	$ (0.02)

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Weighted average shares outstanding - diluted	32,634,839	28,428,215
Loss per shares - diluted	$ (0.02)	$ (0.02)

Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Common Stock
Statement [Line Items]
Balance	$ 3,162	$ 2,835
Balance (in Shares)	31,621,242	28,353,215
Issuance of common stock for services	$ 188	$ 8
Issuance of common stock for services (in Shares)	1,875,000	75,000
Issuance of common stock for debt and interest	$ 80
Issuance of common stock for debt and interest (in Shares)	800,000
Deemed dividend for down-round provision in warrants
Common shares to be issued for services	$ 26
Common shares to be issued for services (in Shares)	260,000
Net loss
Balance	$ 3,456	$ 2,843
Balance (in Shares)	34,556,242	28,428,215
Common Stock Payable
Statement [Line Items]
Balance (in Shares)	39,000
Issuance of common stock for services (in Shares)
Common shares to be issued for services (in Shares)	(39,000)
Balance (in Shares)
Additional Paid-in Capital
Statement [Line Items]
Balance	$ 14,740,401	$ 13,508,582
Issuance of common stock for services	224,163	22,492
Issuance of common stock for debt and interest	119,920
Deemed dividend for down-round provision in warrants	2,013
Common shares to be issued for services	38,974
Additional BCF discount for down-round provision on notes	122,531
Investment in Averox	2,539
Net loss
Balance	15,250,540	13,531,074
Accumulated Deficit
Statement [Line Items]
Balance	(15,130,867)	(13,070,148)
Issuance of common stock for services
Issuance of common stock for debt and interest
Deemed dividend for down-round provision in warrants	(2,013)
Common shares to be issued for services
Net loss	(664,534)	(649,643)
Balance	(15,797,414)	(13,719,791)
Balance	(348,304)	441,269
Issuance of common stock for services	224,350	22,500
Issuance of common stock for debt and interest	120,000
Deemed dividend for down-round provision in warrants
Common shares to be issued for services
Additional BCF discount for down-round provision on notes	122,531
Investment in Averox	2,539
Net loss	(664,534)	(649,643)
Balance	$ (543,418)	$ (185,874)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
OPERATING ACTIVITIES
Net loss	$ (664,534)	$ (649,643)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,287	13,659
Issuance of common stock for services	234,100	62,526
Debt discount amortization	331,559
Financing costs	3,500
Loss on deconsolidation	2,539
Loss on equity investment	8,059
Changes in operating assets and liabilities:
Accounts receivable	145,480	82,541
Inventories	(131,758)	58,971
Prepaid	16,620	(713)
Accounts payable	(39,085)	(29,224)
Accounts payable - related parties	42,000	42,000
Accrued liabilities	66,285	51,610
Accrued compensation - officers	45,000	45,000
Customer deposits	5,000	(15,591)
Net cash used in operating activities	66,052	(338,864)
INVESTING ACTIVITIES
Purchase of property and equipment		(12,629)
Cash paid upon deconsolidation	(2,539)
Note receivable	(14,000)
Net cash used in investing activities	(16,539)	(12,629)
FINANCING ACTIVITIES
Net borrowings (repayments) under lines of credit	616	(2,662)
Proceeds from issuance of note payable shareholder	42,300	179,000
Repayments of notes payable	(4,302)	(5,307)
Stock issued for debt issuance
Net cash provided by financing activities	38,614	171,031
NET INCREASE (DECREASE) IN CASH	88,127	(180,462)
CASH
Beginning of period	126,109	246,317
End of period	214,236	65,855
Supplemental disclosures of cash flow information
Taxes paid
Interest paid	27	3,417
Non-cash disclosures:
Common stock issued for conversion of debt and interest	116,500
Deemed dividend on down-round provision on warrants	2,013
Additional BCF on down-round provision on convertible notes payable	$ 122,531

Organization

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Organization

Note 1 – Organization

Organization and Line of Business

US Nuclear Corp., formerly known as APEX 3, Inc., (the “Company” or “US Nuclear”) was incorporated under the laws of the State of Delaware on February 14, 2012.

On May 31, 2016, the Company entered into an Asset Purchase Agreement with Electronic Control Concepts (“ECC”) whereby the Company purchased certain tangible and intangible assets of ECC.

The Company is engaged in developing, manufacturing and selling radiation detection and measuring equipment. The Company markets and sells its products to consumers throughout the world.

Basis Presentation

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Basis Presentation

Note 2 – Basis Presentation

Interim financial statements

Going Concern

Principles of Consolidation

Use of Estimates

Cash and Cash Equivalents

Concentration of credit risk

Accounts Receivable

Inventories

Property and Equipment

Furniture and fixtures		5 years
Leasehold improvement		Lesser of lease life or economic life
Equipment		5 years
Computers and software		5 years

Long-Lived Assets

Goodwill

Derivative Financial Instruments

Investments

Fair Value of Financial Instruments

Revenue Recognition

●

executed contracts with the Company’s customers that it believes are legally enforceable;

●

identification of performance obligations in the respective contract;

●

determination of the transaction price for each performance obligation in the respective contract;

●

allocation the transaction price to each performance obligation; and

●

recognition of revenue only when the Company satisfies each performance obligation.

These five elements, as applied to each of the Company’s revenue category, is summarized below:

●

Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as customer deposits.

See Notes 12 and 13 for disclosures of revenue disaggregated by geographical area and product line.

Customer Deposits

Customer deposits represent cash paid to the Company by customers before the product has been completed and shipped.

Income Taxes

Stock-Based Compensation

Basic and Diluted Earnings Per Share

Segment Reporting

Related Parties

Reclassifications

Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or stockholders’ equity.

Recent Accounting Pronouncements

Inventories

3 Months Ended

Mar. 31, 2023

Inventories [Abstract]

Inventories

Note 3 – Inventories

Inventories at March 31, 2023 and December 31, 2022 consisted of the following:

	March 31,		December 31,
	2023		2022
Raw materials	$	1,148,942	$	1,244,880
Work in Progress		409,674		409,637
Finished goods		597,806		370,127
Total inventories	$	2,156,422	$	2,024,664

At March 31, 2023 and December 31, 2022, the inventory reserve was $0.

Property and Equipment

3 Months Ended

Mar. 31, 2023

Property and Equipment [Abstract]

Property and Equipment

Note 4 – Property and Equipment

The following are the details of the property and equipment at March 31, 2023 and December 31, 2022:

	March 31,			December 31,
	2023			2022
Furniture and fixtures	$	148,033		$	148,033
Leasehold Improvements		50,091			50,091
Equipment		237,418			237,418
Computers and software		39,482			39,482
		475,024			475,024
Less accumulated depreciation		(469,810	)		(468,523	)
Property and equipment, net	$	5,214		$	6,501

Investments

3 Months Ended

Mar. 31, 2023

Investments [Abstract]

Investments

Note 5 – Investments

MIFTEC

MIFTI

Grapheton

Information regarding Grapheton as of and for the three months ended March 31, 2023 is below:

Current assets	$	8,126
Total assets		13,501
Current liabilities		748,333
Total liabilities		748,333
Total stockholders’ deficiency	$	(722,082	)

Revenue	$	-
Operating expenses		167,190
Other expenses		-
Net loss	$	167,190

Averox

Notes Payable

3 Months Ended

Mar. 31, 2023

Notes Payable [Abstract]

Notes Payable

Note 6 – Notes Payable

The total debt discount amortization recorded on the Company’s notes for the three months ended March 31, 2023 was $331,559.

Future maturities of all notes payable, net of any debt discounts as of March 31, 2023, are as follows:

Years ended December 31,
2023	$	510,135
2024		-
2025		-
2026		-
2027		-
Thereafter		-
	$	510,135

Note Payable to Shareholder

3 Months Ended

Mar. 31, 2023

Note Payable to Shareholder [Abstract]

Note Payable to Shareholder

Note 7 – Note Payable to Shareholder

Line of Credit

3 Months Ended

Mar. 31, 2023

Line of Credit [Abstract]

Line of Credit

Note 8 – Line of Credit

Leases

3 Months Ended

Mar. 31, 2023

Leases [Abstract]

Leases

Note 9 – Leases

Commitments and Contingencies

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 10 – Commitments and Contingencies

Shareholders’ Equity

3 Months Ended

Mar. 31, 2023

Shareholders’ Equity [Abstract]

Shareholders’ Equity

Note 11 – Shareholders’ Equity

Common Stock

During the three months ended March 31, 2023, the Company issued:

●

1,500,000 shares of common stock to its Directors and President, valued at $175,500;

●

800,000 shares of common stock valued at $120,000 in satisfaction of convertible debt and interest;

●

375,000 shares of common stock to consultants for services rendered valued at $48,850. The fair value was determined based on the Company’s stock price on the grant date; and

During the three months ended March 31, 2022, the Company issued:

●

75,000 shares of common stock to consultants for services rendered valued at $22,500. The fair value was determined based on the Company’s stock price on the grant date;

Warrants

The following table summarizes the activity related to warrants:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Warrants		Exercise		Contractual		Intrinsic
	Outstanding		Price		Life		Value
Outstanding, December 31, 2022		2,500,000	$	0.11		2.32	$	-
Granted		-		-		-
Forfeited		-
Exercised		-
Outstanding, March 31, 2023		2,500,000	$	0.11		2.32	$	-
Exercisable, March 31, 2023		2,500,000	$	0.11		2.32	$	-

The following table summarizes information about warrants outstanding and exercisable as of March 31, 2023:

Segment Reporting

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Segment Reporting

Note 12 – Segment Reporting

The following tables summarize the Company’s segment information for the three months ended March 31, 2023 and 2022:

	March 31,
	2023			2022

Sales
Optron	$	243,333		$	56,994
Overhoff		404,373			282,521
Corporate		-			-
	$	647,706		$	339,315

Gross profit
Optron	$	158,520		$	44,082
Overhoff		277,069			183,195
Corporate		-			-
	$	435,589		$	227,277

(Loss)/gain from operations
Optron	$	(53,973	)	$	(218,838	)
Overhoff		36,987			(306,352	)
Corporate		(283,250	)		(121,036	)
	$	(300,236	)	$	(646,226	)

Interest Expenses
Optron	$	5,272		$	2,445
Overhoff		3,656			972
Corporate		13,212			-
	$	22,140		$	3,417

Net income/(loss)
Optron	$	(66,785	)	$	(215,283	)
Overhoff		38,331			(316,324	)
Corporate		(636,080	)		(118,036	)
	$	(664,534	)	$	(649,643	)

	As of March 31, 2023		As of December 31, 2022
Total Assets
Optron	$	1,115,267	$	1,021,817
Overhoff		2,009,915		2,037,988
Corporate		38,783		48,932
	$	3,163,965	$	3,108,737

Goodwill
Optron	$	-	$	-
Overhoff		570,176		570,176
Corporate		-		-
	$	570,176	$	570,176

Geographical Sales

3 Months Ended

Mar. 31, 2023

Geographical Sales [Abstract]

Geographical Sales

Note 13 – Geographical Sales

The geographical distribution of the Company’s sales for the three months ended March 31, 2023 and 2022 is as follows:

	Three Months Ended March 31,
	2023		2022
Geographical sales
North America	$	635,612	$	517,230
Asia		7,915		39,040
Other		4,179		127,501
	$	647,706	$	683,771

Related Party Transactions

3 Months Ended

Mar. 31, 2023

Related Party Transactions

Note 14 – Related Party Transactions

In addition, as of March 31, 2023 and December 31, 2022, the Company had accrued compensation payable to its majority shareholder of $575,000 and $550,000, respectively.

Deconsolidation of Subsidiary

3 Months Ended

Mar. 31, 2023

Deconsolidation of Subsidiary [Abstract]

Deconsolidation of Subsidiary

Note 15 – Deconsolidation of Subsidiary

Upon deconsolidation, the Company recorded a loss of $2,539, reflecting the value of $2,539 in cash in Cali From Above.

Concentrations

3 Months Ended

Mar. 31, 2023

Concentrations [Abstract]

Concentrations

Note 16 – Concentrations

No vendors accounted for more than 10% of the Company’s purchases for the three months ended March 31, 2023 and 2022.

Subsequent Events

3 Months Ended

Mar. 31, 2023

Subsequent Events [Abstract]

Subsequent Events

Note 17 – Subsequent Events

On April 11, 2023, the Company issued 771,845 shares of common stock, by cashless exercise, pursuant to a Warrant Agreement associated with a convertible note payable entered into on May 5, 2022.

On April 26, 2023, the Company issued 420,000 shares to Howard Isaacs in connection with investor relations services provided by the consultant.

On April 26, 2023, the Company issued 50,000 shares to Richard Cavalli in connection with investor relations services provided by the consultant.

On May 25, 2023, the Company issued 517,391 shares of common stock, by cashless exercise, pursuant to a Warrant Agreement associated with a convertible note payable entered into on May 5, 2022.

On June 12, 2023, the Company issued 75,000 shares to Prashant Mehta in connection with the consulting services agreement entered into, by and between US Nuclear Corp and Prashant Mehta.

Accounting Policies, by Policy (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Interim financial statements

Going Concern

Principles of Consolidation

Use of Estimates

Cash and Cash Equivalents

Concentration of credit risk

Accounts Receivable

Inventories

Property and Equipment

Furniture and fixtures		5 years
Leasehold improvement		Lesser of lease life or economic life
Equipment		5 years
Computers and software		5 years

Long-Lived Assets

Goodwill

Derivative Financial Instruments

Investments

Fair Value of Financial Instruments

Revenue Recognition

●

executed contracts with the Company’s customers that it believes are legally enforceable;

●

identification of performance obligations in the respective contract;

●

determination of the transaction price for each performance obligation in the respective contract;

●

allocation the transaction price to each performance obligation; and

●

recognition of revenue only when the Company satisfies each performance obligation.

These five elements, as applied to each of the Company’s revenue category, is summarized below:

●

Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as customer deposits.

See Notes 12 and 13 for disclosures of revenue disaggregated by geographical area and product line.

Customer Deposits

Customer deposits represent cash paid to the Company by customers before the product has been completed and shipped.

Income Taxes

Stock-Based Compensation

Basic and Diluted Earnings Per Share

Segment Reporting

Related Parties

Reclassifications

Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or stockholders’ equity.

Recent Accounting Pronouncements

Basis Presentation (Tables)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Schedule of estimated useful lives of property and equipment

Furniture and fixtures		5 years
Leasehold improvement		Lesser of lease life or economic life
Equipment		5 years
Computers and software		5 years

Inventories (Tables)

3 Months Ended

Mar. 31, 2023

Inventories [Abstract]

Schedule of inventory

	March 31,		December 31,
	2023		2022
Raw materials	$	1,148,942	$	1,244,880
Work in Progress		409,674		409,637
Finished goods		597,806		370,127
Total inventories	$	2,156,422	$	2,024,664

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2023

Property and Equipment [Abstract]

Schedule of property and equipment

	March 31,			December 31,
	2023			2022
Furniture and fixtures	$	148,033		$	148,033
Leasehold Improvements		50,091			50,091
Equipment		237,418			237,418
Computers and software		39,482			39,482
		475,024			475,024
Less accumulated depreciation		(469,810	)		(468,523	)
Property and equipment, net	$	5,214		$	6,501

Investments (Tables)

3 Months Ended

Mar. 31, 2023

Investments [Abstract]

Schedule of information regarding grapheton

Current assets	$	8,126
Total assets		13,501
Current liabilities		748,333
Total liabilities		748,333
Total stockholders’ deficiency	$	(722,082	)

Revenue	$	-
Operating expenses		167,190
Other expenses		-
Net loss	$	167,190

Notes Payable (Tables)

3 Months Ended

Mar. 31, 2023

Notes Payable [Abstract]

Schedule of future maturities of notes payable

Years ended December 31,
2023	$	510,135
2024		-
2025		-
2026		-
2027		-
Thereafter		-
	$	510,135

Shareholders’ Equity (Tables)

3 Months Ended

Mar. 31, 2023

Shareholders’ Equity [Abstract]

Schedule of activity related to warrants

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Warrants		Exercise		Contractual		Intrinsic
	Outstanding		Price		Life		Value
Outstanding, December 31, 2022		2,500,000	$	0.11		2.32	$	-
Granted		-		-		-
Forfeited		-
Exercised		-
Outstanding, March 31, 2023		2,500,000	$	0.11		2.32	$	-
Exercisable, March 31, 2023		2,500,000	$	0.11		2.32	$	-

Schedule of information about options outstanding and exercisable

Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Schedule of company’s segment information

	March 31,
	2023			2022

Sales
Optron	$	243,333		$	56,994
Overhoff		404,373			282,521
Corporate		-			-
	$	647,706		$	339,315

Gross profit
Optron	$	158,520		$	44,082
Overhoff		277,069			183,195
Corporate		-			-
	$	435,589		$	227,277

(Loss)/gain from operations
Optron	$	(53,973	)	$	(218,838	)
Overhoff		36,987			(306,352	)
Corporate		(283,250	)		(121,036	)
	$	(300,236	)	$	(646,226	)

Interest Expenses
Optron	$	5,272		$	2,445
Overhoff		3,656			972
Corporate		13,212			-
	$	22,140		$	3,417

Net income/(loss)
Optron	$	(66,785	)	$	(215,283	)
Overhoff		38,331			(316,324	)
Corporate		(636,080	)		(118,036	)
	$	(664,534	)	$	(649,643	)

	As of March 31, 2023		As of December 31, 2022
Total Assets
Optron	$	1,115,267	$	1,021,817
Overhoff		2,009,915		2,037,988
Corporate		38,783		48,932
	$	3,163,965	$	3,108,737

Goodwill
Optron	$	-	$	-
Overhoff		570,176		570,176
Corporate		-		-
	$	570,176	$	570,176

Geographical Sales (Tables)

3 Months Ended

Mar. 31, 2023

Geographical Sales [Abstract]

Schedule of geographical distribution

	Three Months Ended March 31,
	2023		2022
Geographical sales
North America	$	635,612	$	517,230
Asia		7,915		39,040
Other		4,179		127,501
	$	647,706	$	683,771

Basis Presentation (Details) - USD ($)	3 Months Ended
Basis Presentation (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Accounting Policies [Abstract]
Net loss	$ 664,534
Accumulated deficit	15,797,414
Allowance for doubtful accounts	$ 5,000		$ 5,000
Investments percentage	20.00%
Equity method percentage	50.00%
Sales returns and allowances	$ 0	$ 0
Tax benefit, percentage	50.00%
Warrants outstanding (in Shares)	2,500,000		2,500,000
Share of warrants (in Shares)	7,792,366
Reportable segments	2

Basis Presentation (Details) - Schedule of estimated useful lives of property and equipment	3 Months Ended
	Mar. 31, 2023
Furniture and fixtures [Member]
Basis Presentation (Details) - Schedule of estimated useful lives of property and equipment [Line Items]
Property and equipment	5 years
Leasehold improvement [Member]
Basis Presentation (Details) - Schedule of estimated useful lives of property and equipment [Line Items]
Property and equipment	Lesser of lease life or economic life
Equipment [Member]
Basis Presentation (Details) - Schedule of estimated useful lives of property and equipment [Line Items]
Property and equipment	5 years
Computers and software [Member]
Basis Presentation (Details) - Schedule of estimated useful lives of property and equipment [Line Items]
Property and equipment	5 years

Inventories (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory reserve	$ 0	$ 0

Inventories (Details) - Schedule of inventory - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Schedule of inventories [Abstract]
Raw materials	$ 1,148,942	$ 1,244,880
Work in Progress	409,674	409,637
Finished goods	597,806	370,127
Total inventories	$ 2,156,422	$ 2,024,664

Property and Equipment (Details) - USD ($)	3 Months Ended
Property and Equipment (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,287	$ 3,218
Depreciated property and equipment	$ 440,628

Property and Equipment (Details) - Schedule of property and equipment - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 475,024	$ 475,024
Less accumulated depreciation	(469,810)	(468,523)
Property and equipment, net	5,214	6,501
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	148,033	148,033
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	50,091	50,091
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	237,418	237,418
Computers and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 39,482	$ 39,482

Investments (Details) - USD ($)			1 Months Ended	3 Months Ended		12 Months Ended
Investments (Details) - USD ($)	Mar. 03, 2023	Aug. 03, 2018	Apr. 30, 2019	Mar. 31, 2023	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2019	Dec. 31, 2018
Investments (Details) [Line Items]
Ownership interest		10.00%
Investment amount			$ 500,000
Ownership interest in MIFTEC			0.56%
Grapheton’s common stock (in Shares)				2,552
Shares issued (in Shares)				1,452
Common stock value				$ 601,227
Exchange for common stock, shares (in Shares)					1,100
Out payment					$ 192,500
Ownership, percentage				35.80%
c				$ 8,059
Equity investment amount				0
Shares received (in Shares)	65,000,000
Common Stock [Member]
Investments (Details) [Line Items]
Shares of common stock				235,000
Equity Method Investments Ownership Percentage [Member]
Investments (Details) [Line Items]
Ownership percentage	26.00%
MIFTEC [Member]
Investments (Details) [Line Items]
Investment amount		$ 500,000
Shares of common stock (in Shares)		300,000
Common stock value		$ 594,000
Interest rate								10.00%
Interest in MIFTEC								$ 10,000
Acquisition of manufacturing and supply right								$ 1,084,000
Investment for impairment							$ 9,000
Carrying value of investment				1,000		$ 1,000
MIFTEC [Member] \| Ownership Interest [Member]
Investments (Details) [Line Items]
Ownership interest		10.00%
MIFTI [Member]
Investments (Details) [Line Items]
Shares of common stock (in Shares)			500,000
Investment for impairment							$ 499,000
Carrying value of investment				$ 1,000		$ 1,000
Investment, description			In April 2019, the Company also entered into a Cooperative Agreement with MIFTI whereby the Company acquired certain exclusive manufacturing and supply rights, including thermonuclear fusion-powered reactor for production of electricity per MIFTI designs in return for $500,000, of which $100,000 is payable upon signing, $200,000 within four months of the agreement and $200,000 within nine months of the agreement. The $500,000 is an option to buy a 10% interest in MIFTI for $2,700,000, if completed with 24 months of the agreement date. If the options expire, MIFTI shall issue the Company 500,000 shares of common stock and rescind all other exclusive rights contained in the agreement.
Grapheton, Inc [Member]
Investments (Details) [Line Items]
Shares of common stock (in Shares)				858,896
Exchange for common stock, shares (in Shares)					1,121,071
Common stock value (in Shares)					633,405

Investments (Details) - Schedule of information regarding grapheton - Grapheton [Member]	3 Months Ended
	Mar. 31, 2023 USD ($)
Investments (Details) - Schedule of information regarding grapheton [Line Items]
Current assets	$ 8,126
Total assets	13,501
Current liabilities	748,333
Total liabilities	748,333
Total stockholders’ deficiency	(722,082)
Revenue
Operating expenses	167,190
Other expenses
Net loss	$ 167,190

Notes Payable (Details) - USD ($)			1 Months Ended		3 Months Ended
Notes Payable (Details) - USD ($)	Oct. 10, 2022	May 05, 2022	Apr. 15, 2021	Dec. 26, 2020	Mar. 31, 2023	Dec. 31, 2022
Notes Payable (Details) [Line Items]
Interest rate	5.00%	5.00%	5.00%
Principal and interest payments			$ 4,518
Outstanding notes payable					$ 5,272	$ 5,272
Repaid amount					0
Accrues interest rate				$ 10.89
Balance amount owed					0
Issuance stock warrants		$ 750,000
Debt discounts		$ 550,538			331,559
Additional debt discount					24,558
Total remaining unamortized debt discount					116,951
Stock warrants amount	$ 375,000
Total debt discounts	$ 200,488				207,912
Warrant [Member]
Notes Payable (Details) [Line Items]
Additional debt discount					$ 97,973

Notes Payable (Details) - Schedule of future maturities of notes payable	Mar. 31, 2023 USD ($)
Schedule of future maturities of notes payable [Abstract]
2023	$ 510,135
2024
2025
2026
2027
Thereafter
Total	$ 510,135

Note Payable to Shareholder (Details) - USD ($)	3 Months Ended
Note Payable to Shareholder (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Note Payable to Shareholder (Details) [Line Items]
Majority shareholder loaned an additional	$ 42,300
Mr. Goldstein [Member]
Note Payable to Shareholder (Details) [Line Items]
Due to related parties	$ 916,979	$ 874,679

Line of Credit (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Line of Credit (Details) [Line Items]
Line of credit	$ 307,937	$ 307,321
Line of Credit [Member]
Line of Credit (Details) [Line Items]
Line of credit maximum borrowing amount	$ 400,000
Line of Credit [Member] \| Minimum [Member]
Line of Credit (Details) [Line Items]
Interest rate on line of credit	5.50%
Line of Credit [Member] \| Maximum [Member]
Line of Credit (Details) [Line Items]
Interest rate on line of credit	11.50%

Leases (Details) - USD ($)	3 Months Ended		12 Months Ended
Leases (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Leases (Details) [Line Items]
Operating leases payment	$ 0	$ 0	$ 168,000
Lease expense	$ 42,000	$ 42,000
Weighted average remaining lease terms	1 month 6 days
Weighted average discount rate	8.00%

Shareholders’ Equity (Details)	3 Months Ended
Shareholders’ Equity (Details)	Mar. 31, 2023 USD ($) $ / shares shares
Shareholders’ Equity (Details) [Line Items]
Issued debt	$ 175,500
Common stock shares (in Shares) \| shares	75,000
Common stock issued value	$ 22,500
Issued shares of common stock description	The fair value was determined based on the Company’s stock price on the grant date;
Warrant exercise price (in Dollars per share) \| $ / shares	$ 0.11
Issued shares of common stock per share (in Dollars per share) \| $ / shares	$ 0.14
Exercise price	$ 2,013
Minimum [Member]
Shareholders’ Equity (Details) [Line Items]
Warrant exercise price (in Dollars per share) \| $ / shares	$ 0.11
Convertible Notes [Member]
Shareholders’ Equity (Details) [Line Items]
Shares of common stock (in Shares) \| shares	1,500,000
Consultants [Member]
Shareholders’ Equity (Details) [Line Items]
Shares of common stock (in Shares) \| shares	375,000
Issued debt	$ 48,850
Common stock shares (in Shares) \| shares	800,000
Common stock issued value	$ 120,000

Shareholders’ Equity (Details) - Schedule of activity related to warrants - Warrant [Member]	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Shareholders’ Equity (Details) - Schedule of activity related to warrants [Line Items]
Warrants Outstanding, at Beginning	2,500,000
Weighted Average Exercise Price, at Beginning (in Dollars per share) \| $ / shares	$ 0.11
Weighted Average Remaining Contractual Life, at Beginning	2 years 3 months 25 days
Aggregate Intrinsic Value, at Beginning (in Dollars) \| $
Warrants Outstanding, Granted
Weighted Average Exercise Price ,Granted (in Dollars per share) \| $ / shares
Weighted Average Remaining Contractual Life, Granted
Warrants Outstanding, Forfeited
Warrants Outstanding, Exercised
Warrants Outstanding, at Ending	2,500,000
Weighted Average Exercise Price, at Ending (in Dollars per share) \| $ / shares	$ 0.11
Weighted Average Remaining Contractual Life, at Ending	2 years 3 months 25 days
Aggregate Intrinsic Value, at Ending (in Dollars) \| $
Warrants Outstanding, Exercisable	2,500,000
Weighted Average Exercise Price, Exercisable (in Dollars per share) \| $ / shares	$ 0.11
Weighted Average Remaining Contractual Life, Exercisable	2 years 3 months 25 days
Aggregate Intrinsic Value, Exercisable (in Dollars) \| $

Shareholders’ Equity (Details) - Schedule of information about options outstanding and exercisable - Warrant [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants \| shares	1,500,000
Exercise Price \| $ / shares	$ 0.11

Segment Reporting (Details)	3 Months Ended
Segment Reporting (Details)	Mar. 31, 2023
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Reporting (Details) - Schedule of company’s segment information - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Sales	$ 647,706	$ 339,315
Gross profit	435,589	227,277
(Loss)/gain from operations	(300,236)	(646,226)
Interest Expenses	22,140	3,417
Net income/(loss)	(664,534)	(649,643)
Total Assets	3,163,965		$ 3,108,737
Goodwill	570,176		570,176
Optron [Member] \| Segments [Member]
Segment Reporting Information [Line Items]
Sales	243,333	56,994
Gross profit	158,520	44,082
(Loss)/gain from operations	(53,973)	(218,838)
Interest Expenses	5,272	2,445
Net income/(loss)	(66,785)	(215,283)
Total Assets	1,115,267		1,021,817
Goodwill
Overhoff [Member] \| Segments [Member]
Segment Reporting Information [Line Items]
Sales	404,373	282,521
Gross profit	277,069	183,195
(Loss)/gain from operations	36,987	(306,352)
Interest Expenses	3,656	972
Net income/(loss)	38,331	(316,324)
Total Assets	2,009,915		2,037,988
Goodwill	570,176		570,176
Corporate [Member] \| Segments [Member]
Segment Reporting Information [Line Items]
Sales
Gross profit
(Loss)/gain from operations	(283,250)	(121,036)
Interest Expenses	13,212
Net income/(loss)	(636,080)	$ (118,036)
Total Assets	38,783		48,932
Goodwill

Geographical Sales (Details) - Schedule of geographical distribution - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Geographical sales
Geographical sales total	$ 647,706	$ 683,771
North America [Member]
Geographical sales
Geographical sales	635,612	517,230
Asia [Member]
Geographical sales
Geographical sales	7,915	39,040
Other [Member]
Geographical sales
Geographical sales	$ 4,179	$ 127,501

Related Party Transactions (Details) - USD ($)	3 Months Ended
Related Party Transactions (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Related Party Transactions (Details) [Line Items]
Rent expense	$ 42,000	$ 42,000
Accrued compensation payable	575,000		$ 550,000
Gold Team Inc [Member]
Related Party Transactions (Details) [Line Items]
Payable to related party	$ 322,000		$ 280,000

Deconsolidation of Subsidiary (Details) - USD ($)			3 Months Ended
Deconsolidation of Subsidiary (Details) - USD ($)	Mar. 03, 2023	Mar. 03, 2023	Mar. 31, 2023	Mar. 31, 2022
Deconsolidation of Subsidiary (Details) [Line Items]
Consideration received (in Shares)	65,000,000
Recorded loss			$ (2,539)
Equity Method Investments Ownership Percentage [Member]
Deconsolidation of Subsidiary (Details) [Line Items]
Ownership percentage	26.00%	26.00%
Averox Inc [Member]
Deconsolidation of Subsidiary (Details) [Line Items]
Consideration received (in Shares)		65,000,000
Shares received (in Shares)		65,000,000
Fair value of assets transferred		$ 2,539
Recorded loss		2,539
Cash	$ 2,539	$ 2,539

Concentrations (Details)	3 Months Ended
Concentrations (Details)	Mar. 31, 2023	Mar. 31, 2022
Purchase [Member]
Concentrations (Details) [Line Items]
Concentration percentage	10.00%	10.00%
Customers One [Member] \| Sales [Member]
Concentrations (Details) [Line Items]
Concentration percentage	44.00%	45.80%
Customers Two [Member] \| Sales [Member]
Concentrations (Details) [Line Items]
Concentration percentage	24.00%

Subsequent Events (Details) - shares	Jun. 12, 2023	May 25, 2023	Apr. 26, 2023	Apr. 11, 2023
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Shares issued				771,845
Forecast [Member]
Subsequent Events (Details) [Line Items]
Shares issued	75,000	517,391
Howard Isaacs [Member] \| Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Shares issued			420,000
Richard Cavalli [Member] \| Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Shares issued			50,000